We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
13
Mar 2026
For their discovery of genomic imprinting, developmental biologists Davor Solter and Azim Surani will receive the 2026 Paul Ehrlich and Ludwig Darmstaedter Prize, endowed with €120,000, on March 14 at Frankfurt’s Paulskirche.
13
Mar 2026
Dementia, global trends, community attitudes, conscientious objections by doctors and health facilities, Indigenous perspectives, and organ donation are among agenda topics for the International Conference on Assisted Dying and Other End of Life Care (ICEL5) at QUT next month.
13
Mar 2026
A new, national analysis published in the Aesthetic Surgery Journal suggests the future growth of aesthetic surgery may lie far from traditional luxury markets.
13
Mar 2026
Artificial intelligence could make cancer diagnosis safer and fairer by learning when to defer to human pathologists without overloading them, according to researchers from the University of Surrey and Monash University.